Trials / Completed
CompletedNCT01423370
Safety and Efficacy of YHD1023 in Erectile Dysfunction
Multi-center, Randomized, Double-blind, Placebo/Active-controlled, Phase II Clinical Trial to Assess the Safety and Efficacy of YHD1023 in Patients With Erectile Dysfunction
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 104 (estimated)
- Sponsor
- Yuhan Corporation · Industry
- Sex
- Male
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the safety and efficacy of oral YHD1023 5g or 10g on erectile dysfunction to investigate the optimal recommended dosage. Study period is 12 weeks including 4weeks of follow-up period without treatment. Study patients will fill in the international index of erectile function questionnaire and life satisfaction questionnaires.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | YHD1023 | 5g oral once daily |
| DRUG | YHD1023 | 5g oral twice a day |
| DRUG | YHD1023 | 10g oral once daily |
| DRUG | Cialis | 5mg oral once daily |
| DRUG | Placebo | Oral |
Timeline
- Start date
- 2011-11-01
- Primary completion
- 2013-03-01
- Completion
- 2013-03-01
- First posted
- 2011-08-25
- Last updated
- 2014-07-31
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01423370. Inclusion in this directory is not an endorsement.